Being an in-house specialist has its perks. But focusing on a particular area of the law can reduce a corporate counsel’s exposure to broader swaths of a company and its leaders, lowering the lawyer’s chances of being promoted to the coveted general counsel seat. 

Intellectual property guru Paul Fehlner might be an exception to that rule. He has stepped up from his post as chief IP officer at Axcella Health Inc. to take over as chief legal officer for the clinical-stage biotech firm headquartered in Cambridge, Massachusetts. Fehlner succeeds Heidy Abreu King-Jones, who is now CLO for Provention Bio.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]